adalimumab-aaty (Yuflyma) vs adalimumab-adaz (Hyrimoz)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-aaty (Yuflyma)

Marketed by Celltrion

Approved in Rheumatoid Arthritismonoclonal antibody
Partial signal

NCT03789292 · Phase 3 · completed

This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).

Reported efficacy

American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)

Result source: NCT03789292

adalimumab-adaz (Hyrimoz)

Marketed by Sandoz Group AG and partners

Approved in Rheumatoid Arthritismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aaty (Yuflyma)adalimumab-adaz (Hyrimoz)
ACR2082.7% vs 82.7%vs Humirawk 24 · n 324NCT03789292—Not reported
ACR50—Not reported—Not reported
ACR70—Not reported—Not reported
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-aaty (Yuflyma)
82.7% vs 82.7%vs Humirawk 24 · n 324NCT03789292
adalimumab-adaz (Hyrimoz)
—Not reported

ACR50

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-adaz (Hyrimoz)
—Not reported

ACR70

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-adaz (Hyrimoz)
—Not reported

DAS28-CRP remission

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-adaz (Hyrimoz)
—Not reported

HAQ-DI, change

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-adaz (Hyrimoz)
—Not reported

Modified Sharp score, change

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-adaz (Hyrimoz)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adaz (Hyrimoz): no structured comparison results are available for Rheumatoid Arthritis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-aaty (Yuflyma): 4 of 4 rows · adalimumab-adaz (Hyrimoz): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-aaty (Yuflyma)
Dropout rate
6.5%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
Discontinued due to AEs
2.2%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
Serious AEs
—CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.7%Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
2%Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.3%Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
Most frequent reported AEs
upper respiratory tract infection 5.6%
nasopharyngitis 5.2%
injection site reaction 4.9%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
neutropenia 5%
upper respiratory tract infection 3.3%
urinary tract infection 3%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
neutropenia 5.3%
alanine aminotransferase increased 4.6%
leukopenia 4.6%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-aaty (Yuflyma)

ACR20 82.7% (n=324) vs 82.7% (n=324) Humira @ 24wk
responder rate · % of participants
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 268 Participants as posted
DAS28-CRP -2.738 vs -2.734 Humira score @ 24wk
absolute change · score
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
-2.945 vs -3.074 Humira score @ 52wk
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.983 vs -3.074 Humira score @ 52wk
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · adalimumab-adaz (Hyrimoz)'s landscape